Loading...

IMNN IMUNON INC Product Launches 8-K Filing

MNN

MNN

IMUNON INC

(IMNN)

2025 8-K

Show Summary

Show Summary

Compliance Issues

Voluntary Delisting

Equity Offerings

Primary Offerings

Failure to Meet Listing Sta...

Warrant Exchange

Financial Statements

FDA Study Design

Financial Results

New CMO Appointment

Q3 2024 Results

Management Change

Sales Agreement Termination

Q2 2024 Results

Securities Purchase Agreement

Positive Trial Data Announc...

Annual Meeting Results

Retirement of CFO and Appoi...

Appointment of CEO

Compliance regained with Na...

Amendments to Bylaws

Resignation of CEO

Appointment of Dr. Sébastie...

Annual Meeting Approval

Departure of Directors

Restated Certificate of Inc...

Departure of Officer

Departure of Directors

External Links:

On March 24, 2025, Imunon Inc. announced the finalization of its Phase 3 study design with the FDA for IMNN-001, aimed at treating advanced ovarian cancer, and scheduled a conference call for March 25, 2025, to discuss the trial.

AI Assistant

IMUNON INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.